Clinical Trial: A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations

U.S., Jan. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07313761) titled 'A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations' on Dec. 19, 2025.

Brief Summary: The main objective of this trial is to evaluate the pharmacokinetics (PK) of maridebart cafraglutide administered as a single dose using two different SC presentations in participants living with overweight or obesity.

Study Start Date: Dec. 15, 2025

Study Type: INTERVENTIONAL

Condition: Overweight and Obesity

Intervention: DRUG: Maridebart Cafraglutide

Maridebart cafraglutide will be administered SC.

Recruitment Status: NOT_YET_RECRUITI...